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bridgehead hydrazines have received considerable attention 
because of their pharmacological properties and clinical 
applications.[6,7]For example, 1-arylamino-2, 3-dihydro-
1Hpyrazolo [1,2-b] phthalazine-5,10-dione derivatives 
were reported to possess anti-inflammatory, analgesic, anti 
hypoxic, and antipyretic properties.[8] 
From these points of view, it is interesting to study different 
types of biologically active ligands. In this article, the 
synthesis, characterization, and anti-tumor properties of 
a number of the new ligands have been studied.
MATERIALS AND METHODS
4-pyridinecarboxylic acid hydrazide, salicylaldehyde, 
INTRODUCTION
Nitrogen-containing heterocyclic compounds are 
widespread in nature, and their applications to biologically 
active pharmaceuticals, agrochemicals, and functional 
materials are becoming more and more important.[1] Due to 
the existence of the pyridine ring in the structure of many 
biologically active compounds, for example herbicides 
such as, nicotinic acid, vitamin B5, nicotinamide vitamin 
B6, pyridonal and pyridonamine, and nicotinamide adenine 
dinucleotide, the pyridine ring has been studied extensively, 
both experimentally and theoretically.[2] The development 
of new efficient methods to synthesize N-heterocycles with 
structural diversity is one major interest of modern synthetic 
organic chemists.[3-5] Among a large variety of nitrogen-
containing heterocyclic compounds, those containing 
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ABSTRACT
Using the water eliminated mechanism, reactions of 4-pyridinecarboxylic acid hydrazide and salicylaldehyde, 
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benzaldehyde, cinnamaldehyde, and formaldehyde 
were Merck chemicals, and were used without further 
purification. Organic solvents were of reagent grade. 
Electronic spectra were recorded by Camspec UV–Visible 
spectrophotometer model Wpa bio Wave S2 100. The IR 
spectra were recorded using the FT-IR Bruker Tensor 27 
spectrometer. 1HNMR was recorded on a Bruker AVANCE 
DRX 500 spectrometer. All the chemical shifts were quoted 
in ppm using the high-frequency positive convention; 
1H NMR spectra was referenced to external SiMe4. The 
percent composition of elements was obtained from the 
Microanalytical Laboratories, Department of Chemistry, 
OIRC, Tehran.
Cell culture
The human chronic myeloid leukemia: K562 cell line and 
the human T lymphocyte carcinoma: Jurkat cell line, used 
for treatment with the drugs, was provided. K562 and Jurkat 
cells were grown at 37°C in an atmosphere containing 5% 
CO2, with RPMI-1640 MEDIUM HEPES Modification, 
with L-glutamine and 25 mM HEPES (SIGMA-ALDRICH 
CHEMIE GmbH), supplemented with 10% heat-
inactivated fetal bovine serum (FBS) (Gibco), 2.7% sodium 
bicarbonate, and 500 mg/L ampicillin.
Synthesis of the compounds; General method 
To a magnetically stirred mixture of 4-Pyridinecarboxylic 
acid hydrazide (1.37 g, 10 mmol) in hot methanol (20 mL), 
one type of aldehyde, such as, salicylaldehyde (1.22 g,1 
mmol), benzaldehyde (1.06 g, 1 mmol), cinnamaldehyde 
(1.39 g,1 mmol), or formaldehyde (0.321 g, 1 mmol) was 
added via a syringe and heated for 45 minutes at 60°C. After 
cooling to room temperature, the resulting precipitate was 
filtered and washed with hexane (20 mL) [Figure 1].
Typical procedure for preparation of N4 [(E)-1-(2-
hydroxyphenyl) methylidene] Isonicotinohydrazide 
(3a). The solid residue was dried and crystallized from 
CH3OH (1 : 2) to yield 3a as yellow crystals (1.5 g, 75%). 
Mp 244 – 246.6°C. IR (KBr) (υmax, cm−1): 3181 (O-H) 3003 
(N-H), 1682 (C=O), 1612 (C=N), 1567 and 1489(C=C), 
1289(C-N), 1157(N-N). 1H NMR (CDCl3, Me4Si) : δH 7.1 
and 7.28(5H, 2q, 3JHH = 7.37, arom), 8.16(1H, s, NCH), 8.06 
and 9.33(4H, 2d, 3JHH = 5.28, pyridine), 11.04(1H, d, OH), 
12.99(1H, s, NH). 13C NMR (CDCl3, Me4Si) : δC 117.14, 
119.65, 128.24, 130.62, and 155.74 (arom), 126.05, 138.92, 
and 148.79 (pyridine), 151.2(C11), 165.28(OCN). Anal. calcd 
for C13H11N3O2 (241.26) : C, 64.66; H, 4.55; N, 17.40%. 
Found: C, 64.98; H, 4.87; N, 17.73%.
N4-[(E)-2-Phenylethylidene] Isonicotinohydrazide 
(3b). White crystals(1.76 g, 88%). Mp 184 – 187°C. IR 
(KBr) (υmax, cm−1) : 3198 (N-H), 1700 (C=O), 1600 (C=N), 
1489 and 1447(C=C), 1283(C-N), 1148(N-N). 1H NMR 
(CDCl3, Me4Si) : δH 3.62(2H, d, 3JHH = 6.64Hz, CHCH2), 
660(1H, t, tNCH), 6.72 and 7.13 (5H,2q,  3JHH = 7.05 
Hz, arom), 8.46 and 9.21(4H,2d, 3JHH = 5.28, pyridine), 
9.09(1H, s, NH). 
13C NMR(CDCl3, Me4Si):  δC 34.31(C12), 126.9, 127.23, 
127.43, and 136.33 (arom), 122.82, 143.02, 151.06 
(pyridine), 154.87(NCH), 165.44(OCN). Anal. calcd for 
C13H11N3O (225.27) : C, 69.25; H, 4.88; N, 18.64%. Found: 
C, 69.63; H, 5.11; N, 18.92%.
N 4[(E,2E)-3-Phenyl-2-propenylidene] 
Isonicotinohydrazide (3c). Yellow crystals (1.84 g, 
92%). Mp 200 – 203.3°C. IR (KBr) (υmax, cm−1) : 3233 
(N-H), 1676(C=O), 1640 (C=N), 1451(C=C), 1308(C-
N), 1174(N-N). 1H NMR (CDCl3, Me4Si) : δH 6.06(1H, 
t, CHC), 6.94(1H, d, NCH), 7.51(1H, q,  3JHH = 15.97, 
CHCH), 7.25 and 7.44(5H, 2q, 3JHH = 2.12, 5.28, arom), 
8.50 and 9.21(4H, 2d,  3JHH =7.83, pyridine).  13C NMR 
(CDCl3, Me4Si) : δC 124.76(C13), 127, 128.92, 129.14, and 
135.81(arom), 130.42(C12), 144.62(C11), 122.83, 143.55 and 
151.06(pyridine), 165.05(OCN). Anal. calcd for C15H13N3O 
Figure 1: Synthesis route of compounds
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(251.30): C, 62.70; H, 5.17; N, 16.71%. Found: C, 63.02; 
H, 5.34; N, 17.07%.
N4[(E)ethylidene] Isonicotinohydrazide (3d). White 
crystals (1.3 g, 65%). Mp 244 – 246.6°C. IR (KBr) (υmax, 
cm−1): 3026 (N-H), 1660 (C=O), 1600 (C=N), 1410(C=C), 
1300(C-N), 1164(N-N). 1H NMR (CDCl3, Me4Si): δH 7.55 
and 6.52(2H, 2s, 2JHH = 8.45, NCH), 8.45 and 9.21(4H, 2d, 
3JHH = 5.28, pyridine), 9.25(1H, s, NH). 13C NMR (CDCl3, 
Me4Si) : δC 122.82, 143.6, and 151.06 (pyridine), 136.21(C11), 
165.6(OCN). Anal. calcd for C7H7N3O (149.14): C, 56.32; 
H, 4.69; N, 28.16%. Found: C, 56.65; H, 4.93; N, 28.43%.
In vitro activities 
The compounds were assayed for cytotoxicity in vitro against 
K562 (human chronic myeloid leukemia) cells and Jurkat 
(human T lymphocyte carcinoma) cells.
The two cell lines were provided by the Pasteur Institute 
Laboratory of Natural and Biomimetic in Iran. The 
procedure for cytotoxicity studies was similar to that 
reported earlier.[9] Briefly, in order to calculate the 
concentration of each drug that produced a 50% inhibition 
of cell growth (IC50), 190 mL of cell suspension (5 × 
104 cell/mL) was exposed to various concentrations 
of compounds dissolved in sterile Ethanol. The final 
concentration of Ethanol in the growth medium was 2% 
(v/v) or lower; the concentrations were without effect on 
cell replication.[10,11] After incubation periods of 72 hours 
for all cell lines, the cell concentrations were determined 
both in the control and in drug-treated cultures. All 
experiments were carried out six times and six series.
RESULTS AND DISCUSSION
Preparation of  NHPM, NPI, NPPI, and NEI 
compounds
The reaction of aldehydes with 4-pyridinecarboxylic acid 
hydrazide, results in the formation of Isonicotinohydrazide 
compounds by the water eliminated mechanism. These 
compounds are quite stable and can be stored without any 
appreciable change. These are insoluble in common organic 
solvents, such as, dichloromethane, chloroform, hexane, 
and benzene. However, they are soluble in ethanol, THF, 
DMSO, and DMF. Their structures have been characterized 
by elemental analysis, 1H NMR, 13CNMR, and IR. Their 
elemental analyses are in agreement with their proposed 
formula. The spectral data of the compounds have a good 
relationship with the literature data. 
NHPM, NPI, NPPI, and NEI compounds have been tested 
against two human cancer cell lines : K562 and Jurkat. The 
IC50 cytotoxicity values of the compounds were compared 
with those found for starting organic bases as well as for 
some of the anti-cancer agents used nowadays.[10-12]
Cytotoxicity studies
The general method used for testing on anti-tumor 
properties of these compounds is the standard testing 
method that has been previously described in greater detail: 
After 12 hours of pre-incubation at 37°C in 5% CO2 and 
100% humidity atmosphere, the new compounds were 
added in the following concentration ranges:
0.1 – 610 µM for NHPM, 0.1 – 680 µM for NPI, 0.1 – 450 
µM for NPPI, and 0.1 – 300 µM for NEI. 
The compounds were first dissolved in ethanol and then 
filtrated. The incubation continued up to 72 hours and 
at the end of this period, the IC50 for each compound 
was measured using Trypan blue. The IC50 value was the 
compound concentration needed for killing 50% of the 
tumor cells that were determined by comparison of the 
number of tumor cells in the control plate (blank plate : 
the sample plate without compound) and test plate. The 
corresponding IC50 and IC90 (50 and 90% inhibitory dose) 
values are shown in Table 1.
CONCLUSION
It is clear from the earlier discussion that NHPM, NPI, 
NPPI, and NEI compounds offer a new outlook for 
chemotherapy. The results of antitumor activity show 
that the compounds exhibit antitumor properties, and it 
is important to note that they show enhanced inhibitory 
activity. The mechanism by which these compounds act as 
antitumor agents is apoptosis. It has also been proposed 
that concentration plays a vital role in increasing the degree 
of inhabitation.[13-16]
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